Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa
Shireen V. Guide, Mercedes E. González, Işın Sinem Bağcı, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 24, pp. 2211-2219
Open Access | Times Cited: 112

Showing 1-25 of 112 citing articles:

Genomic newborn screening for rare diseases
Zornitza Stark, Richard H. Scott
Nature Reviews Genetics (2023) Vol. 24, Iss. 11, pp. 755-766
Closed Access | Times Cited: 94
The state of cell and gene therapy in 2023
Daniel Chancellor, David Barrett, Ly Nguyen-Jatkoe, et al.
Molecular Therapy (2023) Vol. 31, Iss. 12, pp. 3376-3388
Closed Access | Times Cited: 53
Innovations in the Treatment of Dystrophic Epidermolysis Bullosa (DEB): Current Landscape and Prospects
Ping‐Chen Hou, Nathalie del Agua, Su M. Lwin, et al.
Therapeutics and Clinical Risk Management (2023) Vol. Volume 19, pp. 455-473
Open Access | Times Cited: 31
Emerging Gene Therapeutics for Epidermolysis Bullosa under Development
Johannes Bischof, Markus Hierl, Ulrich Koller
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2243-2243
Open Access | Times Cited: 14
Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review
Andreas Papapetropoulos, Stavros Topouzis, S P H Alexander, et al.
British Journal of Pharmacology (2024) Vol. 181, Iss. 11, pp. 1553-1575
Open Access | Times Cited: 12
Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs
Virginie Baylot, Thi Khanh Le, David Taïeb, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 10
A review of HSV pathogenesis, vaccine development, and advanced applications
Lan Bai, Jiuzhi Xu, Linghui Zeng, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 8
Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa
Arianna Tovar Vetencourt, Ibrahim O. Sayed-Ahmed, J. E. Gomez, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 6, pp. 530-535
Closed Access | Times Cited: 7
IL‐6 levels dominate the serum cytokine signature of severe epidermolysis bullosa: A prospective cohort study
Antonia Reimer, Moritz Hess, Mladen Davidović, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Open Access | Times Cited: 6
Beremagene Geperpavec: First Approval
Sohita Dhillon
Drugs (2023) Vol. 83, Iss. 12, pp. 1131-1135
Closed Access | Times Cited: 16
Type VII Collagen Deficiency in the Oncogenesis of Cutaneous Squamous Cell Carcinoma in Dystrophic Epidermolysis Bullosa
Andrew P. South, Martin Laimer, Mouhamed Gueye, et al.
Journal of Investigative Dermatology (2023) Vol. 143, Iss. 11, pp. 2108-2119
Open Access | Times Cited: 14
Safety of non-replicative and oncolytic replication-selective HSV vectors
Alberto L. Epstein, Samuel D. Rabkin
Trends in Molecular Medicine (2024) Vol. 30, Iss. 8, pp. 781-794
Open Access | Times Cited: 6
Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa
Adam Raymakers, Aaron S. Kesselheim, Arash Mostaghimi, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 3, pp. 297-297
Closed Access | Times Cited: 5
The Versatility of Collagen in Pharmacology: Targeting Collagen, Targeting with Collagen
Francisco Revert‐Ros, Ignacio Ventura, Jesús A. Prieto-Ruiz, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6523-6523
Open Access | Times Cited: 5
Gene therapy for chronic pain management
Yize Li, Ru‐Rong Ji
Cell Reports Medicine (2024), pp. 101756-101756
Open Access | Times Cited: 5
ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa
Kathrin Dieter, Elke Niebergall‐Roth, Cristina Daniele, et al.
Cytotherapy (2023) Vol. 25, Iss. 7, pp. 782-788
Open Access | Times Cited: 12
Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa
Afsheen Khan, Rumaisa Riaz, Ashraf Saad, et al.
Annals of Medicine and Surgery (2023) Vol. 85, Iss. 12, pp. 6298-6301
Open Access | Times Cited: 12
Splicing Modulation via Antisense Oligonucleotides in Recessive Dystrophic Epidermolysis Bullosa
Stefan Hainzl, Lisa Trattner, Bernadette Liemberger, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 761-761
Open Access | Times Cited: 4
Intravenous gentamicin therapy induces functional type VII collagen in patients with recessive dystrophic epidermolysis bullosa: an open-label clinical trial
David T. Woodley, Michelle Hao, Andrew Kwong, et al.
British Journal of Dermatology (2024) Vol. 191, Iss. 2, pp. 267-274
Closed Access | Times Cited: 4
Lipid nanoparticles containing labile PEG-lipids transfect primary human skin cells more efficiently in the presence of apoE
Camilla Hald Gregersen, Razan Mearraoui, Pia Pernille Søgaard, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2024) Vol. 197, pp. 114219-114219
Closed Access | Times Cited: 4
Challenges and progress related to gene editing in rare skin diseases
Josefina Piñón Hofbauer, Christina Guttmann‐Gruber, Verena Wally, et al.
Advanced Drug Delivery Reviews (2024) Vol. 208, pp. 115294-115294
Open Access | Times Cited: 4
Beyond the Surface: A Narrative Review Examining the Systemic Impacts of Recessive Dystrophic Epidermolysis Bullosa
Courtney Popp, William Miller, Cindy Eide, et al.
Journal of Investigative Dermatology (2024) Vol. 144, Iss. 9, pp. 1943-1953
Closed Access | Times Cited: 4
Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa
Catherine Santucci, Madalina Alexandru, Xinyi Chen, et al.
Human Immunology (2024) Vol. 85, Iss. 3, pp. 110805-110805
Open Access | Times Cited: 4
Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa
Amy S. Paller, Shireen V. Guide, Diego Ayala, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 4
Twin Prime Editing Mediated Exon Skipping/Reinsertion for Restored Collagen VII Expression in Recessive Dystrophic Epidermolysis Bullosa
Benjamin J. Steinbeck, Xin D. Gao, Amber McElroy, et al.
Journal of Investigative Dermatology (2024) Vol. 144, Iss. 12, pp. 2764-2777.e9
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top